{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IV+Squamous+Cell+Lung+Carcinoma&page=3", "query": { "condition": "Stage IV Squamous Cell Lung Carcinoma", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 214, "total_pages": 22, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IV+Squamous+Cell+Lung+Carcinoma&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IV+Squamous+Cell+Lung+Carcinoma&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-08T00:44:00.094Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01041781", "title": "Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "celecoxib", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "pemetrexed disodium", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 313, "start_date": "2010-02", "completion_date": "2018-03", "has_results": true, "last_update_posted_date": "2018-07-23", "last_synced_at": "2026-10-08T00:44:00.094Z", "location_count": 400, "location_summary": "Anniston, Alabama • Scottsdale, Arizona • Jonesboro, Arkansas + 266 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01041781" }, { "nct_id": "NCT04216316", "title": "Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lung Non-Small Cell Squamous Carcinoma", "Stage IV Lung Cancer AJCC v8" ], "interventions": [ { "name": "Berzosertib", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2021-04-14", "completion_date": "2027-03-18", "has_results": true, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-08T00:44:00.094Z", "location_count": 34, "location_summary": "Los Angeles, California • Newport Beach, California • Aventura, Florida + 25 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Aventura", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04216316" }, { "nct_id": "NCT04119024", "title": "Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Recurrent Malignant Solid Neoplasm", "Refractory Malignant Solid Neoplasm", "Uveal Melanoma", "Acral Melanoma", "Neuroendocrine Tumors", "Paraganglioma", "Pheochromocytoma", "Adrenocortical Carcinoma", "Pancreatic Neuroendocrine Tumor", "Thyroid Cancer", "Breast Cancer", "Lung Adenocarcinoma", "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Fludeoxyglucose F-18", "type": "OTHER" }, { "name": "IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "Anusha Kalbasi", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 18, "start_date": "2025-10-07", "completion_date": "2026-10", "has_results": false, "last_update_posted_date": "2026-03-17", "last_synced_at": "2026-10-08T00:44:00.094Z", "location_count": 3, "location_summary": "Duarte, California • Los Angeles, California • Stanford, California", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04119024" }, { "nct_id": "NCT01115790", "title": "A Phase 1 Study in Participants With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer", "Squamous Cell Carcinoma", "Carcinoma, Squamous Cell of Head and Neck", "Lung Squamous Cell Carcinoma Stage IV", "Anal Squamous Cell Carcinoma", "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Prexasertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2010-02", "completion_date": "2016-01", "has_results": false, "last_update_posted_date": "2016-05-10", "last_synced_at": "2026-10-08T00:44:00.094Z", "location_count": 5, "location_summary": "Sarasota, Florida • Oklahoma City, Oklahoma • Nashville, Tennessee + 1 more", "locations": [ { "city": "Sarasota", "state": "Florida" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01115790" }, { "nct_id": "NCT00776100", "title": "Radiation Therapy or Observation After Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "clinical observation", "type": "OTHER" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "OTHER", "RADIATION" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 3, "start_date": "2008-10", "completion_date": "2010-09", "has_results": true, "last_update_posted_date": "2017-03-06", "last_synced_at": "2026-10-08T00:44:00.094Z", "location_count": 168, "location_summary": "Scottsdale, Arizona • Hartford, Connecticut • Jacksonville, Florida + 103 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Bloomington", "state": "Illinois" }, { "city": "Canton", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00776100" }, { "nct_id": "NCT02027428", "title": "Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Squamous Cell Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Abraxane (Induction)", "type": "DRUG" }, { "name": "Carboplatin (Induction)", "type": "DRUG" }, { "name": "Abraxane (Maintenance)", "type": "DRUG" }, { "name": "Best Supportive Care (Maintenance)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 427, "start_date": "2014-02-11", "completion_date": "2019-08-01", "has_results": true, "last_update_posted_date": "2020-08-17", "last_synced_at": "2026-10-08T00:44:00.094Z", "location_count": 91, "location_summary": "Huntsville, Alabama • Glendale, Arizona • Tucson, Arizona + 73 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02027428" }, { "nct_id": "NCT00025285", "title": "Combination Chemotherapy Plus Thalidomide in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "thalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 46, "start_date": "2001-11-01", "completion_date": "2004-09-29", "has_results": false, "last_update_posted_date": "2021-09-09", "last_synced_at": "2026-10-08T00:44:00.094Z", "location_count": 5, "location_summary": "Decatur, Illinois • Goldsboro, North Carolina • Winston-Salem, North Carolina + 2 more", "locations": [ { "city": "Decatur", "state": "Illinois" }, { "city": "Goldsboro", "state": "North Carolina" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Greenville", "state": "South Carolina" }, { "city": "Spartanburg", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00025285" }, { "nct_id": "NCT06772623", "title": "Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non Small Cell Lung Carcinoma", "c-MET" ], "interventions": [ { "name": "Telisotuzumab Adizutecan", "type": "DRUG" }, { "name": "Budigalimab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 252, "start_date": "2025-03-06", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-08T00:44:00.094Z", "location_count": 27, "location_summary": "Phoenix, Arizona • Fullerton, California • Oxnard, California + 24 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "Oxnard", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06772623" }, { "nct_id": "NCT01806675", "title": "18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Giant Cell Glioblastoma", "Adult Glioblastoma", "Adult Gliosarcoma", "Male Breast Cancer", "Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma", "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity", "Recurrent Adult Brain Tumor", "Recurrent Basal Cell Carcinoma of the Lip", "Recurrent Colon Cancer", "Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Hypopharyngeal Cancer", "Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Laryngeal Cancer", "Recurrent Lip and Oral Cavity Cancer", "Recurrent Lymphoepithelioma of the Nasopharynx", "Recurrent Lymphoepithelioma of the Oropharynx", "Recurrent Metastatic Squamous Neck Cancer With Occult Primary", "Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity", "Recurrent Nasopharyngeal Cancer", "Recurrent Non-small Cell Lung Cancer", "Recurrent Oropharyngeal Cancer", "Recurrent Pancreatic Cancer", "Recurrent Paranasal Sinus and Nasal Cavity Cancer", "Recurrent Rectal Cancer", "Recurrent Renal Cell Cancer", "Recurrent Salivary Gland Cancer", "Stage IIIA Breast Cancer", "Stage IIIA Non-small Cell Lung Cancer", "Stage IIIB Breast Cancer", "Stage IIIB Non-small Cell Lung Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer", "Stage IV Non-small Cell Lung Cancer", "Stage IV Pancreatic Cancer", "Stage IV Renal Cell Cancer", "Stage IVA Colon Cancer", "Stage IVA Rectal Cancer", "Stage IVA Salivary Gland Cancer", "Stage IVB Colon Cancer", "Stage IVB Salivary Gland Cancer", "Stage IVC Salivary Gland Cancer", "Tongue Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "18F-fludeoxyglucose (18F-FDG)", "type": "DRUG" }, { "name": "18F-FPPRGD2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanjiv Sam Gambhir", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2013-03-04", "completion_date": "2019-04", "has_results": true, "last_update_posted_date": "2019-10-03", "last_synced_at": "2026-10-08T00:44:00.094Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01806675" }, { "nct_id": "NCT03987555", "title": "Paclitaxel Therapeutic Drug Monitoring in Cancer Patients", "overall_status": "SUSPENDED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Solid Tumor, Adult", "Metastatic Nonsmall Cell Lung Cancer", "Anatomic Stage IV Breast Cancer AJCC v8", "Metastatic Cervical Carcinoma", "Metastatic Ovarian Carcinoma", "Malignant Uterine Neoplasm", "Vulvar Cancer", "Invasive Breast Cancer", "Metastatic Breast Carcinoma", "Prognostic Stage IV Breast Cancer AJCC v8", "Recurrent Breast Carcinoma", "Recurrent Cervical Carcinoma", "Recurrent Lung Non-Small Cell Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Vulvar Carcinoma", "Stage IV Cervical Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Vulvar Cancer AJCC v8", "Stage IV Ovarian Cancer AJCC v8", "Stage IVA Cervical Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVA Ovarian Cancer AJCC v8", "Stage IVA Vulvar Cancer AJCC v8", "Stage IVB Cervical Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Stage IVB Ovarian Cancer AJCC v8", "Stage IVB Vulvar Cancer AJCC v8", "Vulva Squamous Cell Carcinoma" ], "interventions": [ { "name": "Blood draws", "type": "OTHER" }, { "name": "QLQ-CIPN20 Survey", "type": "OTHER" }, { "name": "PR-CTCAE Survey", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2019-11-11", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-08-13", "last_synced_at": "2026-10-08T00:44:00.094Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03987555" } ] }